INT173393

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.24
First Reported 2003
Last Reported 2011
Negated 0
Speculated 1
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 1.03
Pain Relevance 0.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (Itgam) nucleus (Itgam)
Anatomy Link Frequency
neutrophils 4
internal 2
Itgam (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Inflammation 88 89.28 High High
spinal dorsal horn 3 74.68 Quite High
analgesia 9 65.44 Quite High
cytokine 13 58.72 Quite High
Analgesic 17 57.44 Quite High
Thermal hyperalgesia 12 50.80 Quite High
Nerve growth factor 67 50.00 Quite Low
local anesthetic 16 50.00 Quite Low
Hyperalgesia 5 44.36 Quite Low
corticosteroid 5 39.96 Quite Low
Disease Link Frequency Relevance Heat
Injury 52 99.78 Very High Very High Very High
INFLAMMATION 98 89.28 High High
Adhesions 105 88.12 High High
Hypersensitivity 15 60.44 Quite High
Hyperalgesia 18 50.80 Quite High
Asthma 15 45.16 Quite Low
Occupational Lung Diseases 5 35.12 Quite Low
Infection 10 33.92 Quite Low
Ganglion Cysts 19 32.00 Quite Low
Neuropathic Pain 28 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In ropivacaine-treated CCI rats, the immunoreactivity for CD11b was significantly decreased compared with saline-treated CCI rats (37.8 ± 1.9 a.u. for ropivacaine treatment and 64.2 ± 1.7 a.u. for saline treatment; p < 0.001; n = 4; Figure 2a and 2b).
Negative_regulation (decreased) of CD11b Binding (immunoreactivity) of associated with injury
1) Confidence 0.24 Published 2011 Journal Mol Pain Section Body Doc Link PMC3022746 Disease Relevance 0.58 Pain Relevance 0.25
We initially examined if the decrease in binding of CD11b and CD16b antibodies was also observed with intracellular as well as cell surface localized molecules.
Spec (examined) Negative_regulation (decrease) of CD11b Spec (examined) Binding (binding) of
2) Confidence 0.15 Published 2003 Journal BMC Immunol Section Body Doc Link PMC152650 Disease Relevance 0 Pain Relevance 0
This altered antibody binding may reflect reduced affinity of CD11b for its counter and accessory receptors.
Negative_regulation (reduced) of CD11b Binding (affinity) of
3) Confidence 0.15 Published 2003 Journal BMC Immunol Section Body Doc Link PMC152650 Disease Relevance 0.21 Pain Relevance 0.10
With PAF activated neutrophils, feG treatment decreased binding of antibodies for CD11b (17% at 10-11M), and CD16b (33% at 10-11M), and when basal control binding was subtracted (Net MFI) the decreases were 34% and 164%, respectively.
Negative_regulation (decreased) of CD11b Binding (binding) of in neutrophils
4) Confidence 0.11 Published 2003 Journal BMC Immunol Section Body Doc Link PMC152650 Disease Relevance 0.09 Pain Relevance 0
Figure 6 shows that feG reduced binding of CD11b antibody to the cell surface, whereas binding to the internal pool of this marker was not altered.
Negative_regulation (reduced) of CD11b Binding (binding) of in internal
5) Confidence 0.11 Published 2003 Journal BMC Immunol Section Body Doc Link PMC152650 Disease Relevance 0 Pain Relevance 0
The peptide feG reduced basal binding of CD11b to 896 ± 183 and 158 ± 29 for the peritoneal and blood neutrophils, respectively.
Negative_regulation (reduced) of CD11b Binding (binding) of in neutrophils
6) Confidence 0.11 Published 2003 Journal BMC Immunol Section Body Doc Link PMC152650 Disease Relevance 0.15 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox